Xefocam, 8 mg 30 pcs

XEFOCAM is an NSAID of oxicam class; it has anti-inflammatory, analgesic, antipyretic and antiaggregant effect.

Inhibits proinflammatory factors, decreases platelet aggregation; inhibits COX1 and COX2, disrupts arachidonic acid metabolism, decreases Pg production both in inflammatory focus and healthy tissues; inhibits exudative and proliferative phases of inflammation.

Indications

Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, articular syndrome with exacerbation of gout, bursitis, tenosynovitis.

Pain syndrome (weak and moderate intensity): arthralgia, myalgia, neuralgia, lumbago, sciatica, migraine, toothache and headache, algodismenorrhea, pain from injuries, burns.

Feverish syndrome (“colds” and infectious diseases).

Pharmacological effect

XEFOCAM – NSAIDs of the oxicam class; has anti-inflammatory, analgesic, antipyretic and antiplatelet effects.

Suppresses pro-inflammatory factors, reduces platelet aggregation; inhibiting COX1 and COX2, disrupts the metabolism of arachidonic acid, reduces the production of Pg both at the site of inflammation and in healthy tissues; suppresses the exudative and proliferative phases of inflammation.

Special instructions

During the treatment period, it is necessary to monitor the condition of the gastrointestinal tract in order to prevent ulcerogenic effects or gastrointestinal bleeding.

The risk of ulcerogenic effects can be reduced by the simultaneous administration of omeprazole or H2-histamine receptor blockers, synthetic analogs of Pg (misoprostol).

During treatment, monitoring of the peripheral blood picture and the functional state of the liver and kidneys is necessary. In patients with renal failure (plasma creatinine concentration 150-300 µmol/l), dosage adjustment and regular monitoring of renal function are required.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study. Retains Na+, K+, Li+ and water in the body, which can worsen the course of arterial hypertension and heart failure, and in people taking Li+ drugs, increase the severity of the side effects of Li+ salts. Elderly patients, as well as those with arterial hypertension, require regular blood pressure monitoring.

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Lornoxicam

Composition

1 tablet contains lornoxicam 8 mg.

Contraindications

Known hypersensitivity/allergy to lornoxicam or one of the components of Xefocam;
history of hypersensitivity to acetylsalicylic acid or other NSAIDs;
hemorrhagic diathesis or bleeding disorders, as well as previous operations associated with the risk of bleeding or incomplete hemostasis;
peptic ulcer of the stomach and duodenum in the acute phase;
nonspecific ulcerative colitis;
severe liver dysfunction;
moderate or severe renal impairment (serum creatinine level >300 µmol/l);
hypovolemia or dehydration;
confirmed or suspected cerebral hemorrhage;
bronchial asthma;
heart failure;
hearing loss;
deficiency of glucose-6-phosphate dehydrogenase;
pregnancy;
breastfeeding period;
children under 18 years of age.
With caution:
arterial hypertension;
anemia.

Side Effects

From the gastrointestinal tract and liver: abdominal pain, diarrhea, dyspepsia, nausea, vomiting; in rare cases – flatulence, dry mouth, gastritis, esophagitis, the formation of peptic ulcers and/or bleeding in the gastrointestinal tract (including rectal), stomatitis, glossitis, colitis, dysphagia, hepatitis, pancreatitis, liver dysfunction.

Allergic reactions: possible skin rashes, hypersensitivity reactions accompanied by shortness of breath, tachycardia, bronchospasm, Stevens-Johnson syndrome, exfoliative dermatitis, angitis, fever, allergic rhinitis, lymphadenopathy.

From the central nervous system: rarely – dizziness, headache, drowsiness, agitation, sleep disturbances, tinnitus, hearing loss, dysarthria, hallucinations, migraine, peripheral neuropathy, syncope, aseptic meningitis.

From the senses: blurred vision, conjunctivitis.

From the peripheral blood and coagulation system: rarely – leukopenia, thrombocytopenia.

Metabolism: rarely – increased sweating, chills, change in body weight.

From the cardiovascular system: rarely – arterial hypertension, tachycardia, peripheral edema.

From the urinary system: rarely – dysuria, in some cases – glomerulonephritis, papillary necrosis and nephrotic syndrome with transition to acute renal failure, interstitial nephritis, crystalluria, polyuria.

Interaction

Reduces the effectiveness of uricosuric drugs, enhances the effect of anticoagulants, antiplatelet agents, fibrinolytics, side effects of MCS and GCS, estrogens; reduces the effect of antihypertensive drugs and diuretics; enhances the hypoglycemic effect of sulfonylurea derivatives.

Increases the concentration of Li+ and methotrexate in the blood. Reduces the renal clearance of digoxin. Cimetidine increases plasma concentrations of lornoxicam.

Antacids and cholestyramine reduce absorption. Myelotoxic drugs enhance the manifestations of hematotoxicity of the drug.

Overdose

Symptoms: increased side effects from the central nervous system and digestive system, acute renal failure.

Treatment: gastric lavage, activated carbon, symptomatic therapy. Dialysis is ineffective.

Storage conditions

At 15–25 °C

Shelf life

5 years

Manufacturer

Takeda GmbH, Germany